ReviewNeurodegenerative disease management2019
Diagnostic evaluation and monitoring of patients with posterior cortical atrophy.
Review in Neurodegenerative disease management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Functional network contributions to longitudinal tau spread in Posterior Cortical Atrophy.NPJ dementia · 2026Article
- The Heterogeneity of Reading and Spelling Deficits in Posterior Cortical Atrophy.Brain sciences · 2025Article
- Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy.Alzheimer's research & therapy · 2024Article
- Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy.medRxiv : the preprint server for health sciences · 2024Article
- Pisa Syndrome Secondary to Drugs: A Scope Review.Geriatrics (Basel, Switzerland) · 2024Review
- Auditory naming is impaired in posterior cortical atrophy and early-onset Alzheimer's disease.Frontiers in neuroscience · 2024Article
- Language uncovers visuospatial dysfunction in posterior cortical atrophy: a natural language processing approach.Frontiers in neuroscience · 2024Article
- Anterior dorsal attention network tau drives visual attention deficits in posterior cortical atrophy.Brain : a journal of neurology · 2023Article
- Diagnosis and Management of Posterior Cortical Atrophy.Current treatment options in neurology · 2023Review
- Verbal Encoding Deficits Impact Recognition Memory in Atypical "Non-Amnestic" Alzheimer's Disease.Brain sciences · 2022Article
- Primary and Secondary Progressive Aphasia in Posterior Cortical Atrophy.Life (Basel, Switzerland) · 2022Article
- Development of the Colorado posterior cortical questionnaire within an Alzheimer's disease study cohort.Journal of clinical and experimental neuropsychology · 2022Article
- In It Together: A Qualitative Meta-Synthesis of Common and Unique Psychosocial Stressors and Adaptive Coping Strategies of Persons With Young-Onset Dementia and Their Caregivers.The Gerontologist · 2022Article
- Recent update on the heterogeneity of the Alzheimer's disease spectrum.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Outdoor green space exposure and brain health measures related to Alzheimer's disease: a rapid review.BMJ open · 2021Review
- Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report.BMC neurology · 2020Article
- Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum.Neuropsychologia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Posterior cortical atrophy (PCA) is a progressive neurocognitive syndrome, most commonly associated with the loss of complex visuospatial functions. Diagnosis is challenging, and international consensus classification and nomenclature for PCA subtypes have only recently been reached. Presently, no established treatments exist. Efforts to develop treatments are hampered by the lack of standardized methods to monitor illness progression. Although measures developed from work with Alzheimer's disease and other dementias provide a foundation for diagnosing and monitoring progression, PCA presents unique challenges for clinicians counseling patients and families on clinical status and prognosis, and experts designing clinical trials of interventions. Here, we review issues facing PCA clinical research and care, summarize our approach to diagnosis and monitoring of disease progression, and outline ideas for developing tools for these purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.